Skip to main content
SpringerLink
Log in

The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population

  • MULTIMEDIA REPORT
  • Published:
Journal of Interventional Cardiac Electrophysiology Aims and scope Submit manuscript

Abstract

Purpose

The use of oral anticoagulation (OAC) in the elderly population with atrial fibrillation (AF) treated in long-term care (LTC) facilities is inconsistent. We examined the magnitude and sources of the gap between indicated and prescribed OAC in the elderly population with AF.

Methods

We retrospectively scanned the electronic medical record (EMR) and pharmacy data of 25 LTC facilities in Ontario, Canada. The diagnosis of AF was drawn from EMR. Different attributable risk factors for possible failure to prescribe OAC were examined.

Results

In total, 3378 active resident data were examined in the 25 LTC facilities. All the residents were ≥65 years old with mean age of 85 ± 8 years and 2449 (72%) were female. We identified 433 (13%) residents with AF with mean age 87 ± 7 years and mean CHADS2 score of 3 ± 1. Out of all residents with AF, 273 (63%) were on OAC therapy. Residents were mostly treated with warfarin (N = 114 (42%)), rivaroxaban (N = 71 (26%)) or apixaban (N = 62 (23%)) followed by dabigatran (N = 26 (10%)). Antiplatelet drugs as the only stroke prevention therapy were used in 88 (20%) residents, and 28 (6%) residents were on anticoagulation and antiplatelet drugs. Seventy-two (17%) residents were not on any antiplatelet or antithrombotic therapy. None of the potential attributable risks identified consistently correlated with the failure to prescribe indicated therapy.

Conclusions

This data set suggests that 37% of eligible elderly LTC residents failed to receive recommended stroke prevention therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042–6.

    Article  PubMed  Google Scholar 

  2. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke J Cereb Circ. 2005;36:1115–9.

    Article  Google Scholar 

  3. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol. 2014;177:91–9.

    Article  PubMed  Google Scholar 

  4. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.

  5. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114–30.

    Article  PubMed  Google Scholar 

  6. Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ. 2001;323:1218–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461–8.

    Article  CAS  PubMed  Google Scholar 

  8. Friberg L, Rosenqvist M, Lindgren A, Terent A, Norrving B, Asplund K. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke J Cereb Circ. 2014;45:2599–605.

    Article  CAS  Google Scholar 

  9. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  10. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e531S-75S.

  11. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60:738–46.

    Article  CAS  PubMed  Google Scholar 

  12. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62.

    Article  CAS  PubMed  Google Scholar 

  13. Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016;45:77–83.

    Article  PubMed  Google Scholar 

  14. Angaran P, Dorian P, Tan MK, Kerr CR, Green MS, Gladstone DJ, et al. The risk stratification and stroke prevention therapy care gap in Canadian atrial fibrillation patients. Can J Cardiol. 2016;32:336–43.

    Article  PubMed  Google Scholar 

  15. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM registry. Circ J Offic J Japan Circ Soc. 2011;75:1328–33.

    Google Scholar 

  16. Hsu JCMTMKKF, Katz DF, Marzec LN, Lubitz SA, Gehi AK, Turakhia MP, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016.

  17. Mahmud A, Bennett K, Okechukwu I, Feely J. National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing. Br J Clin Pharmacol. 2007;64:706–9.

    Article  PubMed  PubMed Central  Google Scholar 

  18. McAlister FA. The end of the risk–treatment paradox? A rising tide lifts all boats. JACC. 2011;58(17):1766–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arrhythmia Services, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Room E241, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada

    Mohammed Shurrab, Eugene Crystal, Ilan Lashevsky & David Newman

  2. Arrhythmia Services, Cardiology Department, An-Najah National University Hospital, Faculty of Medicine and Health Sciences, Nablus, Palestine

    Mohammed Shurrab

  3. Medical Pharmacies Group Limited, Toronto, ON, Canada

    Denis O’Donnell & Hrishikesh Navare

  4. Extendicare, Toronto, ON, Canada

    Paula Neves

  5. Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada

    Rasha Khatib

Authors
  1. Mohammed Shurrab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene Crystal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Denis O’Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hrishikesh Navare
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paula Neves
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rasha Khatib
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ilan Lashevsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed Shurrab.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Sources of funding

None

Additional information

Abstract presentation

The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population in Ontario. AHA Conference. Circulation. 2015;132:A17022

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 61 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shurrab, M., Crystal, E., O’Donnell, D. et al. The gap between indicated and prescribed stroke prevention therapies in a high-risk geriatric population. J Interv Card Electrophysiol 48, 261–266 (2017). https://doi.org/10.1007/s10840-017-0223-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10840-017-0223-0

Keywords

Search

Navigation